EMA Rejects Alzheimer’s Drug After Trial Falls Short

by | Dec 12, 2025 | Health

Spread the love
Despite reported slowing of progression, regulators said the evidence on the novel oral agent blarcamesine did not support a positive benefit-risk balance.
Medscape News Europe

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments